Maria Giulia Zampino

Author

Also Known As

M G Zampino, M. G. Zampino, M. Giulia Zampino, M. Zampino, M.G. Zampino, MARIA ZAMPINO, Maria G Zampino, Maria G. Zampino, Maria Giulia Zampino, Maria Zampino

176

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

European Institute of Oncology Istituti di Ricovero e Cura a Carattere Scientifico University of Milan Istituto Oncologico Veneto Fondazione IRCCS Istituto Nazionale dei Tumori

About

Maria Giulia Zampino is an author at European Institute of Oncology specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	39	1.6K
2	Health Sciences	7	8	387
3	Nursing	1	1	41
4	Social Sciences	1	1	41
5	Biomedical Engineering	1	1	17

Maria Giulia Zampino

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial Christophe Louvet, Roberto Labianca, Pascal Hammel, Journal of Clinical Oncology	2005	948
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death Chiara Pozzi, Alessandro Cuomo, Ilaria Spadoni, Nature Medicine Tumor BiologyCancer ImmunosurveillanceChemotherapy TriggersMedicineImmunology	2016	269
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study John H. Strickler, Andrea Cercek, Salvatore Siena, The Lancet Oncology OncologyMedicinePathologyColorectal CancerMetastatic Colorectal Cancer	2023	217
CT Perfusion for the Monitoring of Neoadjuvant Chemotherapy and Radiation Therapy in Rectal Carcinoma: Initial Experience Massimo Bellomi, Giuseppe Petralia, Angelica Sonzogni, Radiology	2007	171
Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. Emilio Bajetta, Angelo Di Leo, Maria Giulia Zampino, Journal of Clinical Oncology	1994	152
Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study C. Bokemeyer, Igor Bondarenko, J.T. Hartmann, Journal of Clinical Oncology Surgical OncologyCetuximab 400Cancer ManagementImmunologyPathology	2007	101
Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. Roberto Biffi, Nicola Fazio, Fabrizio Luca, PubMed	2010	89
Lung Metastases From Colorectal Cancer: Analysis of Prognostic Factors in a Single Institution Study Maria Giulia Zampino, Patrick Maisonneuve, Paola Simona Ravenda, The Annals of Thoracic Surgery Prognostic FactorsMedicinePathologyColorectal CancerSingle Institution Study	2014	83
FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial Alberto Sobrero, Sara Lonardi, Gerardo Rosati, Journal of Clinical Oncology Surgical OncologyItalian ThreeGastroenterologyPathologyPharmacotherapy	2018	67
Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma Giacomo Puppa, Patrick Maisonneuve, Angelica Sonzogni, British Journal of Cancer	2007	54

Page 1